Literature DB >> 20484156

MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients.

Christine Voellenkle1, Jeroen van Rooij, Claudia Cappuzzello, Simona Greco, Diego Arcelli, Luca Di Vito, Guido Melillo, Roberta Rigolini, Elena Costa, Filippo Crea, Maurizio C Capogrossi, Monica Napolitano, Fabio Martelli.   

Abstract

MicroRNAs (miRNAs) are noncoding RNAs that act as negative regulators of gene expression. Interestingly, specific alterations of miRNA expression have been found in failing hearts of different etiologies. The aim of this study was to identify the miRNA expression pattern of peripheral blood mononuclear cells (PBMCs) derived from chronic heart failure (CHF) patients affected by ischemic (ICM) and nonischemic dilated (NIDCM) cardiomyopathy. The expression profile of 257 miRNAs was assessed in 7 NIDCM patients, 8 ICM patients, and 9 control subjects by quantitative real-time PCR. Significantly modulated miRNAs were validated by using an independent set of 34 CHF patients (NIDCM = 19, ICM = 15) and 19 control subjects. Three miRNAs (miR-107, -139, and -142-5p) were downmodulated in both NIDCM and ICM patients versus control subjects. Other miRNAs were deregulated in only one of the CHF classes analyzed compared with control subjects: miR-142-3p and -29b were increased in NIDCM patients, while miR-125b and -497 were decreased in ICM patients. Bioinformatic analysis of miRNA predicted targets and of gene expression modifications associated with CHF in PBMCs indicated a significant impact of the miRNA signature on the transcriptome. Furthermore, miRNAs of both the NIDCM and the ICM signature shared predicted targets among CHF-modulated genes, suggesting potential additive or synergistic effects. The present study identified miRNAs specifically modulated in the PBMCs of NIDCM and ICM patients. Intriguingly, most of these miRNAs were previously reported as deregulated in human and/or mouse failing hearts. The identified miRNAs might have a potential diagnostic and/or prognostic use in CHF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484156     DOI: 10.1152/physiolgenomics.00211.2009

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  63 in total

Review 1.  Epigenetic regulation and measurement of epigenetic changes.

Authors:  Kimberly E Stephens; Christine A Miaskowski; Jon D Levine; Clive R Pullinger; Bradley E Aouizerat
Journal:  Biol Res Nurs       Date:  2012-06-03       Impact factor: 2.522

Review 2.  Circulating microRNAs: novel biomarkers for cardiovascular diseases.

Authors:  Jiahong Xu; Jiangmin Zhao; Graham Evan; Chunyang Xiao; Yan Cheng; Junjie Xiao
Journal:  J Mol Med (Berl)       Date:  2011-12-08       Impact factor: 4.599

Review 3.  MicroRNAs: redefining mechanisms in cardiac disease.

Authors:  Gerald W Dorn
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 4.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

5.  Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1β in heart failure.

Authors:  Kenneth Bilchick; Hema Kothari; Aditya Narayan; James Garmey; Abdullah Omar; Brian Capaldo; Coleen McNamara
Journal:  Cardiovasc Res       Date:  2020-06-01       Impact factor: 10.787

Review 6.  Epigenetic mechanisms underlying cardiac degeneration and regeneration.

Authors:  Pankaj Chaturvedi; Suresh C Tyagi
Journal:  Int J Cardiol       Date:  2014-02-20       Impact factor: 4.164

7.  Hypoxamirs and mitochondrial metabolism.

Authors:  Katherine A Cottrill; Stephen Y Chan; Joseph Loscalzo
Journal:  Antioxid Redox Signal       Date:  2014-02-03       Impact factor: 8.401

8.  A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes.

Authors:  Ahmed S Bayoumi; Kyoung-Mi Park; Yongchao Wang; Jian-Peng Teoh; Tatsuya Aonuma; Yaoliang Tang; Huabo Su; Neal L Weintraub; Il-Man Kim
Journal:  J Mol Cell Cardiol       Date:  2017-11-07       Impact factor: 5.000

9.  microRNAs in ischaemic cardiovascular diseases.

Authors:  Simona Greco; Germana Zaccagnini; Christine Voellenkle; Fabio Martelli
Journal:  Eur Heart J Suppl       Date:  2016-04-29       Impact factor: 1.803

10.  MicroRNA-203 enhances coxsackievirus B3 replication through targeting zinc finger protein-148.

Authors:  Maged Gomaa Hemida; Xin Ye; Huifang M Zhang; Paul J Hanson; Zhen Liu; Bruce M McManus; Decheng Yang
Journal:  Cell Mol Life Sci       Date:  2012-07-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.